Grm7 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
--- [1]
This page provides comprehensive information about this gene. See the content below for detailed information. [2]
title: GRM7 Gene [3]
description: GRM7 encodes metabotropic glutamate receptor 7 (mGluR7), a Group III mGluR with high expression in presynaptic terminals where it acts as an autoreceptor regulating glutamate release. [4]
tags: gene, glutamate receptor, GPCR, synaptic signaling [5]
--- [6]
The GRM7 gene encodes mGluR7 (Glutamate Metabotropic Receptor 7), a member of the metabotropic glutamate receptor family. These receptors are class C G-protein coupled receptors (GPCRs) that play crucial roles in modulating synaptic transmission and neuronal excitability throughout the central nervous system.
Metabotropic glutamate receptors (mGluRs) are divided into three groups based on their pharmacology and G-protein coupling:
The GRM7 gene shows characteristic expression patterns in the brain, with highest levels in regions relevant to alzheimer's disease. This regional specificity underlies its functional roles in specific neural circuits.
mGluR7 has been implicated in several neurodegenerative and neuropsychiatric disorders:
mGluR7 is a promising drug target for:
Conn PJ, et al. "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol. 2022. DOI: 10.1146/annurev-pharmtox-052120-013257
Niswender CM, Conn PJ. "Metabotropic glutamate receptors: therapeutic targets for Alzheimer's disease." Neuropharmacology. 2023. DOI: 10.1016/j.neuropharm.2022.109256
Lu Y, et al. "Group I metabotropic glutamate receptors in Parkinson's disease: pathophysiology and therapeutic potential." Acta Neuropathol Commun. 2021. DOI: 10.1186/s40478-021-01247-x
GRM7 (mGluR7) shows widespread expression in the brain with high levels in regions involved in情绪 and motor control:
Single-cell RNA sequencing data from the Allen Brain Atlas shows GRM7 expression in:
| Region | Expression Level | Data Source |
|---|---|---|
| Cerebral cortex | High | Human MTG |
| Hippocampus | High | Human MTG |
| Basal ganglia | High | Mouse Brain |
| Thalamus | Medium-High | Mouse Brain |
| Brainstem | High | Mouse Brain |
mGluR7 functions as an inhibitory autoreceptor:
mGluR7 signaling involves:
| Pathway | Effect | Outcome |
|---|---|---|
| Gi/o inhibition | ↓ cAMP | Reduced release probability |
| GIRK activation | Hyperpolarization | Reduced calcium influx |
| VGCC inhibition | ↓ Ca²⁺ entry | Less neurotransmitter release |
mGluR7 has unique characteristics:
mGluR7 involvement in AD:
mGluR7 as therapeutic target:
mGluR7 and seizure disorders:
| Agent Type | Examples | Stage | Indication |
|---|---|---|---|
| PAMs | AM-908, MMPIP | Preclinical | Cognitive enhancement |
| NAMs | ADX71743 | Preclinical | Anxiety, addiction |
| Agonists | L-AP4 | Research | Neuroprotection |
mGluR7 shares Class C GPCR structure:
| Model | Application | Phenotype |
|---|---|---|
| GRM7 KO | Loss-of-function | Increased seizure susceptibility |
| GRM7 tg | Overexpression | Protected from excitotoxicity |
| Conditional KO | Region-specific | Circuit-specific effects |
The study of Grm7 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent PubMed-indexed publications (2024-present):
Nicoletti F, et al. "Metabotropic glutamate receptors: from signaling to pathology." Prog Neurobiol. Prog Neurobiol. 2021. ↩︎
Luscher C, Huber KM. "Group 1 metabotropic glutamate receptor-dependent long-term potentiation." Neuropharmacology. Neuropharmacology. 2020. ↩︎
Simonyi A, et al. "Group I metabotropic glutamate receptors in neurodegeneration and neuroinflammation." Neuropharmacology. Neuropharmacology. 2020. ↩︎
Stocchi F, et al. "Metabotropic glutamate receptors and Parkinson's disease: opportunities for therapeutic intervention." CNS Drugs. CNS Drugs. 2023. ↩︎
Wang H, et al. "Targeting metabotropic glutamate receptors for neuroprotective therapy in Parkinson's disease." Prog Neuropsychopharmacol Biol Psychiatry. Prog Neuropsychopharmacol Biol Psychiatry. 2022. ↩︎
Wu J, et al. "Metabotropic glutamate receptor modulation and neuroprotection: challenges and opportunities." Expert Opin Ther Targets. Expert Opin Ther Targets. 2021. ↩︎